
Erythropoietin-derived peptide without hematopoietic effects — neuroprotector and tissue repair agent with unique safety profile.
Ranges cited in research literature. Not a usage recommendation. For research use only.
ARA-290, international nonproprietary name cibinetide, is a linear eleven-amino-acid peptide derived from helix B of erythropoietin (EPO). It was designed by Michael Brines and Anthony Cerami at Araim Pharmaceuticals to separate EPO's two functions: the hematopoietic one, which raises hematocrit and carries thrombotic risk, and the tissue-protective one. ARA-290 retains the second and leaves the first untouched, because it does not bind the classical homodimeric EPO receptor.
Its target is the so-called innate repair receptor, a heterodimer of one EPO-receptor subunit and the common β chain of the cytokine receptor (βcR), expressed only in tissues under damage or stress. Activating it attenuates local inflammation, reduces apoptosis and favors repair. Its plasma half-life is barely two minutes, yet the signal it triggers lasts hours, a singular pharmacological trait that shaped trial design.
It is one of the few catalog compounds with controlled clinical trials: Phase 2 in sarcoidosis-associated small fiber neuropathy (improved corneal nerve fiber density and symptoms) and in diabetic neuropathy, with good tolerability and no effect on hematocrit. It holds orphan-drug designation but no approval in any country. Renova distributes it for research only.
| Class | Non-hematopoietic peptide derived from erythropoietin helix B |
| Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 aa; N-terminal pyroglutamate) |
| CAS | 1208243-50-8 |
| Names | Cibinetide (INN) · ARA 290 · pHBSP |
| Target | Innate repair receptor (EPOR–βcR); no affinity for the homodimeric EPOR |
| Half-life | ≈ 2 minutes in plasma; prolonged signaling effect |
| Clinical development | Phase 2 in small fiber neuropathy (sarcoidosis) and diabetic neuropathy; orphan designation |
| Regulatory status | Not approved in any country |
No. It was designed precisely to avoid that: it does not bind the homodimeric EPO receptor that controls red-cell production, but a different receptor (EPOR–βcR) that appears only in damaged tissue. In clinical trials hematocrit did not change.
Because the signal it starts by activating the innate repair receptor persists for hours after the peptide has left the plasma. It is an example of a drug with very short pharmacokinetics and long pharmacodynamics; that is why trials evaluated it with once-daily administration.
In sarcoidosis-associated small fiber neuropathy, Phase 2 trials described increased corneal nerve fiber density and improved neuropathic symptoms versus placebo; in diabetic neuropathy, similar signals. Tolerability was good. No Phase 3 has been completed and there is no approval.
It is a pyroglutamate: the N-terminal glutamate cyclized onto itself. That modification protects the end of the peptide from aminopeptidases and is part of the original design; without it the molecule would degrade even faster.
Related reading: ARA-290 (Cibinetide): The Innate Repair Receptor
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty